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Background: Maraviroc is an HIV-1 coreceptor antagonist that has shown good efficacy and tolerability in
treatment-naive and treatment-experienced patients harboring CCR5-tropic virus. The use of Maraviroc in treatment
simplification in patients with suppressed plasma HIV-1 RNA requires analysis of HIV-1 DNA. Coreceptor tropism
testing is often performed remotely at reference laboratories. In this study paired whole blood stored at + 4°C and
at−20°C were compared as a source for genotypic coreceptor tropism testing.
Methods: Two hundred paired whole blood samples from different patients were analysed. Each sample was
stored in two different conditions: one aliquot was stored at−20°C until spin column DNA extraction (WB20) and
one aliquot was stored at +4°C for two weeks and then placed at room temperature (22-24°C) for two days before
DNA extraction (WB4). Subsequently, a fragment encompassing the HIV-1 gp120 V3 domain was amplified by a
singlicate nested PCR followed by triplicate nested PCR in the negative samples. A randomly selected panel of 20
paired WB4 and WB20 duplicate amplification products were sequenced and coreceptor tropism was inferred by
geno2pheno [coreceptor].
Results: WB20 yielded a higher amount of DNA than WB4 (median [IQR] values 332.5 ng/μl [117.5-401] and
107 ng/μl [56.6-318], respectively; P < 0.001). However, the DNA purity was higher for WB4 than for WB20 (median
distance from the optimal OD260/280 ratio, 0.14 [0.07-0.79] and 0.96 [0.36-1.10], respectively; P < 0.0001). The number
of samples successfully amplified was 152 (76.0%) for WB20 and 155 (77.5%) for WB4 with the first PCR and 179
(89.5%) for WB20 and 181 (90.5%) for WB4 (P = ns) following subsequent triplicate analysis. The inferred coreceptor
tropism was concordant in 18 out of 20 paired WB4 and WB20 samples. Two samples yielded discordant results,
consistent with the discordance rate within duplicates from the same sample source (2/20 with WB4 and 1/20 with
WB20) due to the inherent gp120 V3 variability.
Conclusions: Storing whole blood at +4°C for up to two weeks and shipping at room temperature is a convenient
method for obtaining HIV-1 gp120 V3 sequence information via testing at a remote laboratory in patients with
suppressed viremia.
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Cell infection by the Human Immunodeficiency Virus
type 1 (HIV-1) requires interaction between the viral en-
velope surface glycoprotein (gp120) and a cellular core-
ceptor (CCR5 or/and CXCR4) together with the CD4
receptor molecule. HIV-1 can use CCR5 (R5 virus), or
CXCR4 (×4 virus) or both (dual mixed or DM virus)
coreceptors to enter target cells [1]. Determination of
HIV-1 coreceptor usage is required prior to therapy with
Maraviroc, the only CCR5 antagonist currently licensed
for treatment of HIV-1 infection [2]. Presently, genotypic
tropism testing is the most widely used method in
Europe to define HIV-1 coreceptor tropism, based on
the strict correlation between HIV-1 V3 env region
sequence and coreceptor usage [3].
In Europe, Maraviroc is licensed for therapy-exper-
ienced patients but not yet for first-line therapy. Mara-
viroc containing regimens are also used in patients with
suppressed viremia [4]. This strategy is supported by the
safety profile of this drug, decreasing treatment toxicity
[5]. In such patients, however, HIV coreceptor tropism
cannot be determined on plasma RNA as recommended
but proviral DNA can be considered as an alternative
source of viral genetic material [6]. Previous studies have
indeed shown a good correlation between genotype
based tropism results obtained from paired HIV-1 DNA
and RNA [7,8] and preliminary evidence of the clinical
relevance of proviral HIV-1 DNA tropism testing in the
context of suppressed viremia has been provided [9,10].
While genotypic coreceptor tropism testing is gaining
wide acceptance, this procedure may not always be avai-
lable in all clinical settings. Standard sample handling
for remote testing requires storage of frozen specimens
and shipment in dry ice, adding complexity to routine
analysis. In this study, whole blood storage at +4°C and
shipment at room temperature was evaluated as a more
convenient handling method for remote HIV-1 DNA
coreceptor tropism testing. To test this strategy, 200
paired whole blood samples were analysed.
Methods
A total of 200 whole blood samples were collected from
200 patients with suppressed viremia as defined as HIV-
1 RNA <40 copies/ml by the Abbott RealTime assay. Pa-
tients signed an informed consent allowing anonymous
use of samples for research purposes and the study was
approved by the Ethical Committee of the Siena Univer-
sity Hospital. Of these, 43 had HIV-1 RNA target de-
tected and 157 had HIV-1 RNA target not detected. For
each sample, (i) one 500-microliter whole blood aliquot
was frozen within 4 hours after drawing and stored
at−20°C until DNA extraction (WB20) and (ii) one 500-
microliter whole blood aliquot was stored at +4°C for
two weeks within 4 hours after drawing, then placed atroom temperature (22-24°C) for two days (WB4) and
subjected to the same DNA extraction procedure.
Whole blood DNA was extracted by using the High
Pure Viral Nucleic Acid Kit (Roche Applied Science, ca-
talogue number 11858874001) following the manufac-
turer instructions. The choice of this system was based
on previous comparisons showing that DNA yield is in-
creased with respect to the QIAamp DNA Blood Mini
Kit (Qiagen) (data not shown). To make the procedure
as straightforward as possible, the DNA extracted was
not measured and 5 of the total 50 microliters obtained
from the extraction procedure were directly used for
PCR. However, DNA concentration and purity were
subsequently measured spectrophotometrically (Nano-
Photometer P360, Implen) as a post hoc analysis to
compare the yield of the two extraction procedures.
A 421-bp fragment encompassing the HIV-1 gp120 V3
domain was amplified by nested PCR. Blood DNA ex-
tracted from WB4 or WB20 was amplified by a nested
PCR protocol using primer P150 (5′-AATGTCAGC
ACAGTACAATGYACACAT-3′, coordinates 6945-6971
in the reference HXB2 genome) and P151 (5′-CTACTT
TATATTTATATAATTCAYTTCTC-3′, 7661-7689) in
the outer amplification step and primer P537 (5′-CAG
TACARTGYACACATGGAAT-3′, 6955-6976) and P538
(5′-TAGAAAAATTCYCCTCYACAATTAAA-3′, 7350-
7375) in the inner amplification step. Both outer and
inner PCR mixtures contained 50 mM Tris–HCl (pH 9.0
at 25°C), 50 mM KCl, 2 mM MgCl2, 200 μM each dNTP,
1.25 U GoTaq polymerase (Promega) and 8 pmol each
primer. After an initial denaturation step of 3 minutes at
94°C, the cycling profile was 20 seconds at 52°C, 40
seconds at 72°C and 30 seconds at 94°C for both steps
but the number of cycles was 25 in the outer PCR and
30 in the inner PCR. PCR products were resolved on
1.5% agarose gels and stained with ethidium bromide.
Each DNA extract was first subjected to a singlicate
amplification. When the expected PCR product was not
obtained, a triplicate amplification was performed again
using 5 μl as the template, to increase overall sensitivity
of the assay.
To ensure that the differences in the two sample pro-
cessing procedures do not have any impact on the distri-
bution of the virus variants with different coreceptor
tropism, a panel of 20 paired WB4 and WB20 amplifica-
tion products were randomly selected and subjected to
bidirectional Sanger sequencing using the same inner
PCR primers P537 and P538 and BigDye 1.1 chemistry.
Sequencing products were resolved on an ABI3130xl in-
strument (Applied Biosystems, Foster, CA, USA) and
handled by the SeqMan module of the DNASTAR 7.1.0
package (DNASTAR Inc., Madison, WI, USA). Since
intrasample variability in the V3 region using population
sequencing has been reported [11], two distinct PCR
Table 1 Amplification of the gp120 V3 sequence from the 200 whole blood samples stored at +4°C (WB4) and at −20°C
(WB20) using a first singlicate plus second triplicate testing approach
Sample type Positive with first
singlicate test
Positive with second
triplicate test
Negative with both first singlicate
and second triplicate test
Overall % of
positive cases
WB4 155 26 19 90.5
WB20 152 27 21 89.5
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the WB4 vs. WB20 comparison. Coreceptor tropism was
assigned by the geno2pheno [coreceptor] algorithm with
a 10% False Positive Rate cut-off [12], based on the lo-
west of the two FPR values obtained for each sample.
Results and discussion
The number of samples successfully amplified by the
complete procedure was 179 (89.5%) for WB20 and 181
(90.5%) for WB4 (P = ns; chi-square test) (Table 1).
There was no significant difference in the rate of positive
samples with WB4 and WB20, either in the first singli-
cate test or in the subsequent triplicate analysis per-
formed on negative samples. Table 2 shows the details of
the first singlicate amplification and the second triplicate
amplification on the 200 paired WB4 and WB20 sam-
ples. The rate of positive reactions in the subset of sam-
ples tested by triplicate amplification was 48.9% (66/135
reactions) for WB4 and 38.9% (56/144) for WB20
(P = 0.116; chi-square test).
Measurement of all the DNA samples by spectropho-
tometry detected two WB4 cases and six WB20 cases
where the DNA concentration fell below the threshold
of sensitivity of the system. However, in each case the
corresponding WB20 and WB4 sample, respectively, had
detectable DNA. Paired analysis of DNA concentration
for the 192 cases with measurable DNA in both WB4
and WB20 showed that WB20 yielded a higher amount of
DNA compared to WB4 (median [IQR] values 332 ng/μlTable 2 Distribution of results with the first singlicate
and the second triplicate testing on the 200 whole blood
samples stored at +4°C (WB4) and at−20°C (WB20)
First singlicate test Second triplicate test No. of
cases
% of
casesWB4 WB20 WB4 WB20
Positive Positive NA NA 133 66.5
Positive Negative NA Positive 19 9.5
Positive Negative NA Negative 3 1.5
Negative Positive Positive NA 16 8.0
Negative Positive Negative NA 3 1.5
Negative Negative Positive Positive 7 3.5
Negative Negative Positive Negative 3 1.5
Negative Negative Negative Positive 1 0.5
Negative Negative Negative Negative 15 7.5
NA, not applicable (second triplicate test run only on samples which were
negative in first singlicate test).[117-401] and 107 ng/μl [57-318]; P < 0.001, Wilcoxon
signed rank test). By contrast, the DNA purity (as mea-
sured by absolute distance from the optimal 1.8-2.0
OD260/280 ratio [13]) was higher for WB4 than for WB20
(median distance 0.14 [0.07-0.79] and 0.96 [0.36-1.10];
P < 0.0001, Wilcoxon signed rank test). The median DNA
concentration was not statistically different in samples
amplified and not amplified, either for the WB4 (median
99 vs. 212 ng/μl; P = 0.120, Mann–Whitney test) or the
WB20 (341 vs. 327 ng/μl; P = 0.780, Mann–Whitney test)
dataset.
Coreceptor tropism inferred by the geno2pheno
[coreceptor] algorithm was concordant in 18 of 20
randomly selected panel of 20 WB4 and WB20 paired
samples, scoring 11 R5 and 7 non-R5 sequences (Table 3).
Two samples yielded discordant results, one R5 in WB4
and non-R5 in WB20 (patient 8800) and one non-R5 in
WB4 and R5 in WB20 (patient 5100). This was consistent
with the discordance rate detected within duplicate ana-
lysis. Indeed, 2/20 of the WB4 (patients 196 and 5100)
and 1/20 of the WB20 (patient 8800) duplicate sequences
yielded one R5 and one non-R5 FPR value. The median
ratio of highest to lowest FPR value within paired WB4
and WB20 duplicates was also comparable (median [IQR]
1.11 [0.9] for WB4 and 1.00 [0.54] for WB20; P = 0.538,
Wilcoxon signed rank test).
Conclusions
This study shows that prolonged maintenance of whole
blood at +4°C for two weeks and shipping at room
temperature does not decrease the sensitivity of HIV-1 V3
DNA amplification compared with standard whole blood
freezing followed by shipment in dry ice. The testing time
schedule chosen fits well the clinical practice in most in-
fectious diseases units sending samples to remote labora-
tories for genotypic coreceptor tropism.
Although prolonged whole blood storage at +4°C and
shipment at room temperature results in some loss of
DNA, this difference does not affect the V3 DNA ampli-
fication rate by the protocol used in this study. Higher
purity of the DNA extracted from unfrozen vs. frozen
blood, as suggested by the better OD260/280 ratio, likely
explains this observation. Since DNA was not measured
before PCR to make the procedure straightforward, it is
currently uncertain whether and how much measure-
ment and normalization of DNA input can improve
sensitivity. Ultimately, the success of amplification is
Table 3 Geno2pheno [coreceptor] False Positive Rates (FPR) obtained from duplicate sequence analysis (designed A
and B) of a randomly selected panel of 20 paired samples stored at +4°C (WB4) and at−20°C (WB20)
Patient WB4 FPR-A WB4 FPR-B WB4 tropism WB20 FPR-A WB20 FPR-B WB20 tropism
196 7.8 11.7 non-R5 7.9 6.0 non-R5
488 42.6 49.0 R5 49.0 49.0 R5
541 86.2 86.2 R5 87.4 86.2 R5
904 5.8 5.8 non-R5 5.8 5.8 non-R5
1339 10.8 10.8 R5 16.6 10.8 R5
1512 8.5 7.8 non-R5 8.5 8.5 non-R5
5012 7.8 4.8 non-R5 5.8 3.9 non-R5
5100 10.6 8.6 non-R5 12.0 12.0 R5
5656 83.0 83.0 R5 83.0 80.4 R5
6773 83.0 93.5 R5 48.4 48.4 R5
7055 1.7 1.7 non-R5 1.7 1.7 non-R5
8113 91.2 92.8 R5 92.8 92.8 R5
8800 17.1 17.1 R5 17.1 0.2 non-R5
9056 1.5 0.2 non-R5 0.1 1.6 non-R5
9746 17.8 46.7 R5 22.0 73.1 R5
9850 19.1 47.8 R5 47.8 47.8 R5
9880 94.1 95.2 R5 96.0 96.0 R5
10161 90.9 90.9 R5 90.9 90.9 R5
11659 0.1 0.5 non-R5 0.1 0.2 non-R5
11686 23.3 46.8 R5 35.3 23.3 R5
Meini et al. BMC Infectious Diseases 2013, 13:508 Page 4 of 5
http://www.biomedcentral.com/1471-2334/13/508dependent on an optimal balance between the advantage
of a larger DNA input and the possible drawbacks due
to the parallel increase in PCR inhibitors derived from
whole blood. Ideally, a thorough analysis of the interplay
between these factors in individual samples could result
in increased amplification rates. However, the 90% suc-
cess rate obtained here makes the cost-effectiveness of
individual sample analysis questionable, particularly in
the context of suppressed HIV-1 viremia which can be
associated with hardly detectable HIV-1 DNA indepen-
dent from the method used [14].
In summary, storing whole blood at +4°C for up to
two weeks and shipping at room temperature is a
convenient method for obtaining HIV-1 gp120 V3 DNA
sequence information via testing at a remote labora-
tory in patients with suppressed viremia. As expected,
there is no preferential enrichment or loss of any virus
sub-population, as detected by sequence variability and
prediction of coreceptor tropism. In addition, this pro-
cedure can be adapted to amplification of any HIV-1
genome region and be useful also in resource-limited
settings where HIV drug resistance surveillance requires
simple, cost-effective and logistically feasible methods
for sample collection and shipment to remote reference
laboratories. As an additional pilot study (data not
shown) we have obtained successful HIV-1 gp120 V3DNA amplification from 11/11 whole blood samples
stored at +4°C for two weeks and then placed at 37°C
for two days to mimic shipment at the extreme tempera-
tures typical of many resource-limited countries with high
HIV prevalence. This preliminary evidence further sup-
ports straightforward working on HIV DNA without the
need to implement cold chain management, resulting in
expanded access to testing and cost savings.Abbreviations
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